NNNN Anbio Biotechnology

Fundamentals / CIK 0001982708 / USD

Anbio Biotechnology reported $8.65M in revenue and net income of $6.40M for the fiscal year ended December 31, 2025 (up 5.6% year over year), with a 87.2% gross margin and a 66.7% operating margin.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open NNNN in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$23.21M$11.60M$0FY 2022 Revenue: $23.54MFY 2022 Net Income: $10.01M2022FY 2023 Revenue: $6.71MFY 2023 Net Income: $2.25M2023FY 2024 Revenue: $8.19MFY 2024 Net Income: $2.37M2024FY 2025 Revenue: $8.65MFY 2025 Net Income: $6.40M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31
Revenue $8.65M $8.19M $6.71M $23.54M
Cost of Revenue $1.10M $2.30M $3.35M $10.98M
Gross Profit $7.54M $5.89M $3.36M $12.56M
Research & Development $201K $454K $135K $200K
Selling, General & Admin $1.57M $3.44M $1.27M $2.17M
Total Operating Expenses $1.78M $3.89M $1.40M $2.37M
Operating Income $5.77M $2.00M $1.96M $10.20M
Interest Income $142K $338K $165K $42K
Interest Expense -- -- -- $8.0K
Income Before Tax $6.40M $2.37M $2.25M $10.01M
Income Tax Expense $0 $0 $0 --
Net Income $6.40M $2.37M $2.25M $10.01M
Basic EPS $0.15 $0.06 $0.10 $100,112.00
Diluted EPS $0.15 $0.06 $0.10 $100,112.00
Basic Shares Outstanding 43.7M 42.3M 21.4M 100
Diluted Shares Outstanding 43.7M 42.3M 21.4M --

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly income statement rows are available in SEC EDGAR CompanyFacts for NNNN.

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $7.77M $11.76M $9.69M
Short-Term Investments $4.13M $0 --
Cash & Short-Term Investments $11.90M $11.76M $9.69M
Accounts Receivable, Net $3.66M $1.06M $1.88M
Other Current Assets $14.08M $5.68M --
Total Current Assets $30.24M $18.53M $15.75M
Total Non-Current Assets $0 $387K $62K
Total Assets $30.24M $18.92M $15.81M
Accounts Payable $0 $1.63M $827K
Other Current Liabilities $88K $105K $166K
Total Current Liabilities $88K $1.73M $993K
Total Non-Current Liabilities $0 $0 $0
Total Liabilities $88K $1.73M $993K
Retained Earnings $23.58M $17.17M $14.80M
Total Stockholders' Equity $30.16M $17.19M $14.82M
Total Equity $30.16M $17.19M $14.82M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2025-12-31 2024-12-31 2023-12-31
Cash & Cash Equivalents $7.77M $11.76M $9.69M
Short-Term Investments $4.13M $0 --
Cash & Short-Term Investments $11.90M $11.76M $9.69M
Accounts Receivable, Net $3.66M $1.06M $1.88M
Other Current Assets $14.08M $5.68M --
Total Current Assets $30.24M $18.53M $15.75M
Total Non-Current Assets $0 $387K $62K
Total Assets $30.24M $18.92M $15.81M
Accounts Payable $0 $1.63M $827K
Other Current Liabilities $88K $105K $166K
Total Current Liabilities $88K $1.73M $993K
Total Non-Current Liabilities $0 $0 $0
Total Liabilities $88K $1.73M $993K
Retained Earnings $23.58M $17.17M $14.80M
Total Stockholders' Equity $30.16M $17.19M $14.82M
Total Equity $30.16M $17.19M $14.82M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31
Net Income $6.40M $2.37M $2.25M $10.01M
Change in Receivables -$2.59M $820K -$1.88M $718K
Change in Inventory -- -- $354K -$354K
Change in Payables -$1.63M $798K -$581K -$482K
Operating Cash Flow -$6.74M $2.08M $898K $4.45M
Purchases of Investments -- -$35.47M -$18.54M -$16.09M
Investing Cash Flow -$4.20M $337K $1.73M -$1.53M
Common Stock Issued $7.23M $0 $0 --
Financing Cash Flow $6.95M -$345K -$43K --
Net Change in Cash -$3.99M $2.07M $2.59M $2.92M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly cash flow statement rows are available in SEC EDGAR CompanyFacts for NNNN.

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31
Gross Margin 87.2% 71.9% 50.1% 53.4%
Operating Margin 66.7% 24.4% 29.2% 43.3%
Net Profit Margin 74.1% 29.0% 33.6% 42.5%
Return on Equity (ROE) 21.2% 13.8% 15.2% --
Return on Assets (ROA) 21.2% 12.5% 14.3% --
Current Ratio 344.31x 10.71x 15.86x --
Quick Ratio 177.12x 7.41x 11.65x --
Revenue Growth (YoY) +5.6% +21.9% -71.5% --
Gross Profit Growth (YoY) +28.2% +75.1% -73.2% --
Operating Income Growth (YoY) +189.1% +1.8% -80.8% --
Net Income Growth (YoY) +169.9% +5.3% -77.5% --
EPS Growth (YoY) +162.5% -46.7% -100.0% --
Operating Cash Flow Growth (YoY) -423.9% +131.6% -79.8% --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

No quarterly ratios & growth rows are available in SEC EDGAR CompanyFacts for NNNN.
Source: SEC EDGAR CompanyFacts (CIK 0001982708) · from December 31, 2022 Data through December 31, 2025 · synced Nov 20, 2026, 05:46 UTC · Open in terminal